Trials / Terminated
TerminatedNCT02116959
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 3 Months – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules. Researchers want to find out what effects, good and/or bad, the treatment combination has on the patients and their retinoblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | |
| DRUG | Carboplatin | |
| DRUG | Etoposide | |
| DRUG | Vincristine |
Timeline
- Start date
- 2014-07-23
- Primary completion
- 2019-05-25
- Completion
- 2019-05-25
- First posted
- 2014-04-17
- Last updated
- 2020-04-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02116959. Inclusion in this directory is not an endorsement.